


# ALLERGY in ICD-11 NEWSLETTER

## LUCIANA KASE TANNO, PASCAL DEMOLY

The core *Allergy in ICD-11* operational team (Luciana Kase Tanno and Pascal Demoly), is an independent group working for the Allergy specialty worldwide and represents the Joint Allergy Academies\* into the ICD-11 and other WHO classifications. They are now heading the WHO Collaborating Centre on Classification Scientific Support.



ALLERGY in ICD-11  
Coding it right!

TWELFTH EDITION, MARCH 2020

### ADDRESSED TO:

The **Joint Allergy Academies executive committees**:

- European Academy of Allergy and Clinical Immunology (EAACI): Marek Jutel, Ioana Agache, Antonella Muraro, Nikolaos G. Papadopoulos, Peter Hellings
- World Allergy Organization (WAO): Lanny Rosenwasser, Mario Sanchez-Borges, Ignacio Ansotegui, Motohiro Ebisawa
- American Academy of Allergy Asthma and Immunology (AAAAI): Thomas Casale, Robert Lemanske, Thomas Fleisher, James Li, Robert A. Wood, David Lang, David B. Peden
- American College of Allergy, Asthma and Immunology (ACAAI): James Sublet, Bryan L. Martin, Bradley Chipps
- Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI): Hee-Bom Moon, Francis Thien, Yoon-Seok Chang, Ruby Pawankar
- Latin American Society of Allergy, Asthma and Immunology (SLAAI): Juan Carlos Sisul, Edgardo Jares, Maximiliano Gomez, Maria Susana Repka de Ramirez, João Tibiriça
- Asia Pacific Academy of Pediatric Allergy, Respirology & Immunology: Gary
- **Patients' Organization**
- **Junior members groups**
- **The World Health Organization (WHO) representatives/ staff and WHO-Family of International Classifications Network**

\* *Joint Allergy Academies*: American Academy of Allergy Asthma and Immunology (AAAAI), European Academy of Allergy and Clinical Immunology (EAACI), World Allergy Organization (WAO), American College of Allergy Asthma and Immunology (ACAAI), Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), Latin American Society of Allergy, Asthma and Immunology (SLAAI)



## SUPPORT CODING INFORMATION: COVID-19

### SPECIAL EDITION IMMEDIATE CODING IMPLEMENTATION ACTIONS

The twelfth edition of the Allergy in ICD-11 edition is focused on immediate updates on ICD-10 coding tools due to the COVID-19 pandemic. It intends to support all health workers, researchers, public health decision-makers and stakeholders dealing with this new condition.

LKT and PD, as members of the WHO-FIC Council and chairs of the Montpellier WHO Collaborating Centre, received the communication from the WHO on 19<sup>th</sup> March for the immediate implementation of the online ICD-10 and the WHO website. It is our responsibility to support the WHO to disseminate the information and the community actions. Therefore, we would like share the following information:


- **Updates in the ICD-10 related to the COVID-19**

We hope this situation will settle soon, but meanwhile #StaySafe #StayStrong #StayHome when possible.

Besides, we would like to update you regarding the ongoing actions of the ALLERGY in ICD-11 initiative:

- **Montpellier WHO Collaborating Centre (WHO CC) actions**
- **ICD-11 implementation in process**
- **Medical and scientific advisory group (MSAC) activities**
- **Timeline and perspectives**

# COVID-19 IN ICD-10



## B34.2 Coronavirus infection, unspecified site

Excl: COVID-19, virus identified (U07.1)  
COVID-19, virus not identified (U07.2)  
severe acute respiratory syndrome [SARS] (U04.9)

## U04.9 Severe acute respiratory syndrome [SARS], unspecified

Excl: COVID-19, virus identified (U07.1)  
COVID-19, virus not identified (U07.2)

## U07 Emergency use of U07

Note: Codes U00-U49 are to be used by WHO for the provisional assignment of new diseases of uncertain etiology. In emergency situations codes are not always accessible in electronic systems. The specification of category U07 in the way it is done here will make sure this category and the subcategories are available in every electronic system at any time and that they can be used upon instruction by WHO, immediately.

### U07.0 Vaping related disorder

Use additional code, if desired, to identify pneumonia or other manifestations.

#### U07.1 COVID-19, virus identified

Use this code when COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms

Use additional code, if desired, to identify pneumonia or other manifestations.

Excl: Coronavirus infection, unspecified site (B34.2)

Coronavirus as the cause of diseases classified to other chapters (B97.2)

Severe acute respiratory syndrome [SARS], unspecified (U04.9)

#### U07.2 COVID-19, virus not identified

Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available.

Use additional code, if desired, to identify pneumonia or other manifestations

COVID-19 NOS

Excl: COVID-19:

- confirmed by laboratory testing (U07.1)
- Coronavirus infection, unspecified site (B34.2)
- special screening examination (Z11.5)
- suspected but ruled out by negative laboratory results (Z03.8)

#### U07.3 Emergency use of U07.3

#### U07.4 Emergency use of U07.4

#### U07.5 Emergency use of U07.5

#### U07.6 Emergency use of U07.6

#### U07.7 Emergency use of U07.7

#### U07.8 Emergency use of U07.8

#### U07.9 Emergency use of U07.9

# MONTPELLIER COLLABORATING CENTRE FOR CLASSIFICATION SCIENTIFIC SUPPORT

## TIMELINE:

- **June 2018:** the WHO has designated the Department of Pulmonology and Addictology, Division of Allergy, University Hospital of Montpellier, as a WHO Collaborating Centre for Classification Scientific Support, headed by Pascal Demoly and Luciana Kase Tanno.
- **October 2018:** WHO-FIC meeting, Seoul
- **May 2019:** ICD-11 has been adopted
- **June 2019:** WHO CC first report submitted
- **October 2019:** WHO-FIC meeting, Canada

A l'honneur

L'Unité de Pneumologie et Allergologie rejoint l'Organisation Mondiale de la Santé



L'Organisation Mondiale de la Santé (OMS) vient de désigner comme « Centre Collaborateur OMS », l'Unité de Pneumologie et Allergologie du CHU. Le Centre Collaborateur OMS pour le Soutien Scientifique à la Classification sera dirigée par le Pr Pascal DEMOLY et le Dr Luciana KASE TANNO. Cette désignation a pris effet le 22 juin 2018

L'Unité de Pneumologie et Allergologie du CHU de Montpellier a été désigné comme Centre Collaborateur OMS en reconnaissance du travail scientifique et académique du Pr Pascal DEMOLY et du Dr Luciana KASE TANNO en collaboration avec l'OMS et les Sociétés Savantes d'Allergologie depuis 2012. Elle est notamment en charge de la classification internationale scientifique des allergies et hypersensibilités. C'est notamment grâce à ce travail que l'unité a obtenu cette distinction.

Cette nomination comme « Centre Collaborateur » met également en avant le haut niveau de publications scientifiques du CHU de Montpellier sur ce sujet (une vingtaine de communications) et vient aussi souligner un centre académique réputé qui a déjà formé de nombreux étudiants.

Au sein de l'équipe du Pr Pascal DEMOLY, Dr Luciana KASE TANNO est en charge de cette classification internationale scientifique des allergies et hypersensibilités. Pour mener à bien ce travail, une collaboration a été mise en place avec une équipe du Département d'Information Médicale (DIM) du CHU, dirigée par le Pr Nicolas MOLINARI et regroupant les Dr Pierre AUBAS et Grégoire MERCIER, et Sophie BRUEL.

Le rôle d'un « Centre Collaborateur de l'OMS » est d'apporter un soutien aux différents programmes mis en place par l'OMS tant au niveau régional, national et international. Un « Centre Collaborateur » a aussi pour but de renforcer les ressources du pays (en termes d'informations, de recherche, de services...) dans le but de favoriser le développement sanitaire du pays.

Cette nomination vient en complément la désignation de l'Unité de Pneumologie et Allergologie du CHU de Montpellier comme « Centre d'excellence » par le comité de sélection du WAO, World Allergy Organisation fin 2017.

### Contacts:

- Pr Pascal DEMOLY, [p.demoly@chu-montpellier.fr](mailto:p.demoly@chu-montpellier.fr)
- Dr Luciana KASE TANNO, [l.kasetanno@chu-montpellier.fr](mailto:l.kasetanno@chu-montpellier.fr) ou [luciana.tanno@gmail.com](mailto:luciana.tanno@gmail.com)

## The Montpellier WHO CC main actions:


- 1.** Scientific-medical input for the development and maintenance of ICD-11 and other WHO-FIC classifications (ICF, ICHI, ICPC)
- 2.** Quality assurance and field-testing
- 3.** Education and dissemination
- 4.** Implementation support, research and networking

### Examples:

- the Global implementation of the World Health Organization's International Classification of Diseases (ICD)-11: the Allergic and Hypersensitivity Model
- Real-life use of ICD-11



## GLOBAL IMPLEMENTATION OF THE WORLD HEALTH ORGANIZATION'S INTERNATIONAL CLASSIFICATION OF DISEASES (ICD)-11: THE ALLERGIC AND HYPERSENSITIVITY



### CROWDSOURCING THE PIONEER ALLERGIC AND HYPERSENSITIVITY SECTION OF THE ICD-11

We undertook an international crowdsourcing in order to peer review the revised classification, nomenclature and definitions of allergic and hypersensitivity conditions introduced into ICD-11 and to support their global implementation. A further goal was to increase awareness of the revised classification in ICD-11 in order to promote more accurate epidemiological data collection and help improve clinical management of patients with allergic and hypersensitivity disorders.

We received contributions from all the 6 WHO regions and we thank very much the allergy community for their support.

In addition to helping during the implementation phase of the new ICD-11 “Allergic and hypersensitivity conditions” classification, all the comments provided will help to improve the allergic and hypersensitivity conditions classification and to increase awareness by different disciplines of what actions are needed to ensure more accurate epidemiological data and better clinical management of patients with allergic and hypersensitivity disorders.

## **WHO Medical And Scientific Advisory Committee (MSAC)**

- 20 members nominated by the WHO to support advances and use of ICD-11 and other WHO classifications
- Teleconference among the MSAC board members have been ongoing regularly in order to follow up the activities of the committee.
- LKT is in charge of reviewing the conditions scattered across the new *Immune System Disorders* chapter
- Current activity: review the proposals in the ICD-11 platform and discussions when CSAC requires



### **+ TIMELINE**

#### **ICD-11 Global Implementation:**



- **Up to 2022: full official implementation of ICD-11 in the countries health systems (translation, clinical use, diagnostic and coding tools, training programs)**
- **2022-2032: monitoring process**

#### **ICHI and ICF:**

- **Current action quality assurance**

#### **ICPC:**

- **2020: presentation of the ICPC-3**



**\*\* ALLERGY in ICD-11 references:**

- <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1398-9995.2012.02829.x>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405839/>
- <https://onlinelibrary.wiley.com/doi/full/10.1111/all.12386>
- <https://onlinelibrary.wiley.com/doi/full/10.1111/all.12604>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482039/>
- <https://apallergy.org/DOIx.php?id=10.5415/apallergy.2015.5.4.193>
- <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.12834>
- <https://www.sciencedirect.com/science/article/abs/pii/S2213219816000210?via%3Dhub>
- <https://www.sciencedirect.com/science/article/abs/pii/S2213219816000507?via%3Dhub>
- <https://e-aair.org/DOIx.php?id=10.4168/aair.2016.8.4.383>
- <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.12945>
- <https://apallergy.org/DOIx.php?id=10.5415/apallergy.2016.6.3.149>
- <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13006>
- <https://www.sciencedirect.com/science/article/abs/pii/S2213219816302719?via%3Dhub>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977713/>
- <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13093>
- [https://www.annallergy.org/article/S1081-1206\(16\)31273-X/fulltext](https://www.annallergy.org/article/S1081-1206(16)31273-X/fulltext)
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237226/>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301440/>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356259/>
- <https://www.ingentaconnect.com/content/ocean/aap/2017/00000038/00000004%3bjsessionid=fn3kgo1o8nb68.x-ic-live-02>
- <https://onlinelibrary.wiley.com/doi/full/10.1111/all.13335>
- <https://www.tandfonline.com/doi/full/10.1080/1744666X.2018.1520094>
- <https://insights.ovid.com/pubmed?pmid=30730395>
- [https://www.jacionline.org/article/S0091-6749\(19\)30664-5/pdf](https://www.jacionline.org/article/S0091-6749(19)30664-5/pdf)